Phase I/II study of a short course of weekly cisplatin in patients with advanced solid tumours.

Por Planting, A. S., van der Burg, M. E., de Boer-Dennert, M., Stoter, G., Verweij, J.
Publicado em 1993

Diagnostic value of anti-neuronal antibodies for paraneoplastic disorders of the nervous system.

Por Moll, J W, Henzen-Logmans, S C, Splinter, T A, van der Burg, M E, Vecht, C J
Publicado em 1990

Epidermal growth factor receptor in ovarian tumours: correlation of immunohistochemistry with ligand binding assay.

Por Henzen-Logmans, S. C., Berns, E. M., Klijn, J. G., van der Burg, M. E., Foekens, J. A.
Publicado em 1992

A phase II study of epidoxorubicin in colorectal cancer and the use of cyclosporin-A in an attempt to reverse multidrug resistance.

Por Verweij, J., Herweijer, H., Oosterom, R., van der Burg, M. E., Planting, A. S., Seynaeve, C., Stoter, G., Nooter, K.
Publicado em 1991

Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in metastatic colorectal cancer.

Por Planting, A. S., van der Burg, M. E., van den Bent, M. J., de Boer-Dennert, M., Stoter, G., Verweij, J.
Publicado em 1996

A scoring system for immunohistochemical staining: consensus report of the task force for basic research of the EORTC-GCCG. European Organization for Research and Treatment of Canc...

Por van Diest, P J, van Dam, P, Henzen-Logmans, S C, Berns, E, van der Burg, M E, Green, J, Vergote, I
Publicado em 1997

Current sample handling methods for measurement of platinum-DNA adducts in leucocytes in man lead to discrepant results in DNA adduct levels and DNA repair.

Por Ma, J., Verweij, J., Planting, A. S., de Boer-Dennert, M., van Ingen, H. E., van der Burg, M. E., Stoter, G., Schellens, J. H.
Publicado em 1995

Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer

Por van der Burg, M E L, de Wit, R, van Putten, W L J, Logmans, A, Kruit, W H J, Stoter, G, Verweij, J
Publicado em 2002

Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours.

Por Schellens, J. H., Ma, J., Planting, A. S., van der Burg, M. E., van Meerten, E., de Boer-Dennert, M., Schmitz, P. I., Stoter, G., Verweij, J.
Publicado em 1996

Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancer

Por Polee, M B, Eskens, F A L M, van der Burg, M E L, Splinter, T A W, Siersema, P D, Tilanus, H W, Verweij, J, Stoter, G, van der Gaast, A
Publicado em 2002

Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients

Por de Jongh, F E, van Veen, R N, Veltman, S J, de Wit, R, van der Burg, M E L, van den Bent, M J, Planting, ASTh, Graveland, W J, Stoter, G, Verweij, J
Publicado em 2003

Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy

Por Polee, M B, Hop, W C J, Kok, T C, Eskens, F A L M, van der Burg, M E L, Splinter, T A W, Siersema, P D, Tilanus, H W, Stoter, G, van der Gaast, A
Publicado em 2003

Adaptive intrapatient dose escalation of cisplatin in combination with low-dose vp16 in patients with nonsmall cell lung cancer

Por Schellens, J H M, Planting, ASTh, van Zandwijk, N, Ma, J, Maliepaard, M, van der Burg, M E L, de Boer-Dennert, M, Brouwer, E, van der Gaast, A, van den Bent, M J, Verweij, J
Publicado em 2003